142 related articles for article (PubMed ID: 24584350)
1. The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria.
Quak E; Hovhannisyan N; Lasnon C; Fruchart C; Vilque JP; Musafiri D; Aide N
Haematologica; 2014 Jun; 99(6):e84-5. PubMed ID: 24584350
[No Abstract] [Full Text] [Related]
2. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
3. Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging.
Bakhshi S; Bhethanabhotla S; Kumar R; Agarwal K; Sharma P; Thulkar S; Malhotra A; Dhawan D; Vishnubhatla S
J Nucl Med; 2017 Apr; 58(4):577-583. PubMed ID: 27754902
[TBL] [Abstract][Full Text] [Related]
4. Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients.
Quak E; Le Roux PY; Hofman MS; Robin P; Bourhis D; Callahan J; Binns D; Desmonts C; Salaun PY; Hicks RJ; Aide N
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2072-82. PubMed ID: 26219870
[TBL] [Abstract][Full Text] [Related]
5. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
Kostakoglu L; Schöder H; Johnson JL; Hall NC; Schwartz LH; Straus DJ; LaCasce AS; Jung SH; Bartlett NL; Canellos GP; Cheson BD;
Leuk Lymphoma; 2012 Nov; 53(11):2143-50. PubMed ID: 22421007
[TBL] [Abstract][Full Text] [Related]
6. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma.
Rhodes MM; Delbeke D; Whitlock JA; Martin W; Kuttesch JF; Frangoul HA; Shankar S
J Pediatr Hematol Oncol; 2006 May; 28(5):300-6. PubMed ID: 16772881
[TBL] [Abstract][Full Text] [Related]
7. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
[TBL] [Abstract][Full Text] [Related]
8. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
9. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010.
Meignan M; Gallamini A; Haioun C; Polliack A
Leuk Lymphoma; 2010 Dec; 51(12):2171-80. PubMed ID: 21077737
[TBL] [Abstract][Full Text] [Related]
10. Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma.
Yang DH; Jung SH; Ahn JS; Kim YK; Min JJ; Bom HS; Lee JJ; Kim HJ
Chonnam Med J; 2015 Dec; 51(3):109-14. PubMed ID: 26730361
[TBL] [Abstract][Full Text] [Related]
11. Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments.
Zijlstra JM; Boellaard R; Hoekstra OS
Leuk Lymphoma; 2009 Nov; 50(11):1748-9. PubMed ID: 19863171
[TBL] [Abstract][Full Text] [Related]
12. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
13. qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.
Hasenclever D; Kurch L; Mauz-Körholz C; Elsner A; Georgi T; Wallace H; Landman-Parker J; Moryl-Bujakowska A; Cepelová M; Karlén J; Álvarez Fernández-Teijeiro A; Attarbaschi A; Fosså A; Pears J; Hraskova A; Bergsträsser E; Beishuizen A; Uyttebroeck A; Schomerus E; Sabri O; Körholz D; Kluge R
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1301-8. PubMed ID: 24604592
[TBL] [Abstract][Full Text] [Related]
14. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET scan in assessing lymphomas and the application of Deauville Criteria.
Awan UE; Siddiqui N; SaadUllah M; Bashir H; Farooqui ZS; Muzaffar N; Mahmmood MT
J Pak Med Assoc; 2013 Jun; 63(6):725-30. PubMed ID: 23901673
[TBL] [Abstract][Full Text] [Related]
16. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma.
Dunleavy K; Mikhaeel G; Sehn LH; Hicks RJ; Wilson WH
Leuk Lymphoma; 2010 Aug; 51 Suppl 1():28-33. PubMed ID: 20658958
[TBL] [Abstract][Full Text] [Related]
17. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma.
Bhojwani D; McCarville MB; Choi JK; Sawyer J; Metzger ML; Inaba H; Davidoff AM; Gold R; Shulkin BL; Sandlund JT
Br J Haematol; 2015 Mar; 168(6):845-53. PubMed ID: 25382494
[TBL] [Abstract][Full Text] [Related]
18. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
19. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
20. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
